730 results on '"M. Provencio"'
Search Results
2. ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
3. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations
4. 16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial
5. 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials)
6. 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
7. EP16.04-014 NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma
8. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial
9. LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816
10. 947P Follow-up tests’ profitability in NSCLC: Experience of a tertiary hospital
11. Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816
12. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
13. 1630P Effectivity and safety of anti-SARS-CoV2 vaccination in patients with lung cancer: The VAC-CaP observational study (GECP 21/01)
14. 1604P Assessing lung cancer patients' unplanned hospitalizations, a cohort study to find care gaps: Tracking what is trackable
15. P1.15-09 First-line Atezolizumab plus Bevacizumab for Metastatic High-Intermediate TMB in Non-squamous NSCLC. The TELMA Study
16. PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
17. EP04.01-019 Into the Wild: Assessing Acute Care for Lung Cancer Patients, A Cohort Study to Improve Cancer Care at Emergency Department
18. EP08.01-029 NIVIPI-BRAIN, A Phase II Study of Nivolumab plus Ipilimumab Combined with Chemotherapy for Patients with NSCLC and Synchronous Brain Metastases
19. EP08.01-066 Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?
20. EP08.01-065 Prevalence of Non-driver Mutations and Characterization of Patients with Advanced or Metastatic Non-small Cell Lung Cancer
21. 1064P Genomic characterization of first line advanced or metastatic non-small cell lung cancer (aNSCLC) patients (pts) subgroups associated with good/bad prognosis
22. 932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816
23. LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816
24. P2.07-02 RET Fusion Testing with FISH and Real-Time PCR: a Comparison with RNA-Based Next-Generation Sequencing in RET Positive NSCLC
25. OA02.03 Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial
26. 490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
27. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial
28. EP13.01-016 Are Follow-up Tests Useful in NSCLC? Experience of a Tertiary Hospital
29. Impact of Covid-19 in the field of oncology
30. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
31. 42P Real-life data on treatment with poly (ADP-ribose) polymerase inhibitor (iPARP), in patients over 65 years of age with ovarian cancer: A current need
32. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
33. P84.16 Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer
34. P09.12 SARS- CoV2 Impact in a Spanish Lung Cancer Cohort?
35. P25.06 Malignant Pleural Mesothelioma: Patient Characteristics, Treatments and Outcomes from a Spanish Center
36. EP16.04-014 NTRK in Lung Cancer Patients with History of Hodgkin's Lymphoma
37. P1.09-03 Multidisciplinary Thoracic Tumors Board Survey in Spain
38. EP16.02-007 Detection of Clinically Relevant Fusions and Exon Skipping Alterations in Non Small Cell Lung Cancer Patients Liquid Biopsies
39. EP06.01-017 Clinical Impact of SARS-CoV2 Pandemic in the Diagnosis of Early-Stage Thoracic Tumours
40. 947P Follow-up tests’ profitability in NSCLC: Experience of a tertiary hospital
41. MA06.03 Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial
42. Résultats chirurgicaux de l’essai de phase 3 CheckMate 816 (CM 816) : Nivolumab (N) + doublet de chimiothérapie à base de sels de platine (CT) vs CT comme traitement néo-adjuvant du cancer bronchique non à petites cellules (CBNPC) résécable
43. Author response for 'NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment'
44. 2133P Sleep disorders: Evolution in time in early breast cancer (EBC)
45. 2070P Assessment of healthy lifestyle habits in breast cancer patients
46. 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial
47. P40.10 Brain Metastases in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy. Real World Data From a Tertiary Hospital in Spain
48. OA14.01 Family History of Cancer and Lung Cancer: Information from the Thoracic Tumors Registry (TTR Study)
49. P40.12 Cardiotoxicity in Lung Cancer Patients Treated With Immune-Checkpoints Inhibitors
50. P31.03 The Impact of the COVID-19 Pandemic on a Thoracic Tumor Unit of a Tertiary Hospital in Spain
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.